Drugs / NVC-001
NVC-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07606274 | Jun 2026 → Mar 2030 expected | dilated cardiomyopathy 1A | Nuevocor Pte. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NVC-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07606274 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “Adeno-Associated Virus (Serotype 9) Vector Expressing a Dominant Negative SUN1 Transgene” NCT07606274 ↗ |
| Route | Intravenous | “Solution for intravenous infusion” NCT07606274 ↗ |
| Target | SUN1 | “SUN1 transgene” NCT07606274 ↗ |